.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L03A_Immunostimulants.L03AB17_SampeginterferonBeta1a.SampeginterferonBeta1a .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L03A_Immunostimulants.L03AB17_SampeginterferonBeta1a.SampeginterferonBeta1a| name: | SampeginterferonBeta1a | |
| ATC code: | L03AB17 | route: | subcutaneous |
| compartments: | 1 | |
| dosage: | 125 | mg |
| volume of distribution: | 8 | L |
| clearance: | 0.004 | liter/hour/kilogram |
| other parameters in model implementation | ||
Sampeginterferon beta-1a is a long-acting, pegylated form of interferon beta-1a, designed for the treatment of relapsing forms of multiple sclerosis (MS). Pegylation provides prolonged half-life, allowing for less frequent dosing compared to non-pegylated forms. Sampeginterferon beta-1a has been under clinical investigation for MS, but as of 2024, no product with this specific name is approved or marketed.
Estimated pharmacokinetic parameters for a pegylated interferon beta-1a formulation, based on models and properties reported for peginterferon beta-1a in healthy volunteers and MS patients.